Publications by authors named "Alexander Ni"
Article Synopsis
- The study aimed to compare the effectiveness of ustekinumab and anti-TNF agents as first-line treatments in biologic-naïve patients with luminal Crohn's disease, focusing on clinical response rates at 3 months.
- A total of 206 biologic-naïve patients (156 on anti-TNF agents and 50 on ustekinumab) were evaluated, with response rates at 3 months showing 64% for ustekinumab and 86% for anti-TNF agents, indicating a significant advantage for anti-TNF therapy (P = .01).
- The findings suggest that anti-TNF agents lead to higher response rates within 3 months compared to ustekinumab, although no significant
Background: Rates of colectomy for ulcerative colitis have been decreasing, particularly since the advent of biologics, but the subsequent impact of reduced colectomy rates on the development of neoplasms in chronically treated ulcerative colitis colons is unknown.
Purpose: To determine trends in colectomy for colorectal neoplasms in adult patients with ulcerative colitis.
Methods: Adult admissions with ulcerative colitis were identified from the National Inpatient Sample from 1993 to 2015.